PNC-27

  • PNC-27 is a peptide designed to target and bind to the p53 protein, which plays a critical role in tumor suppression. In cancer cells, PNC-27 interacts with the cell membrane and induces cell membrane lysis, specifically targeting malignant cells without affecting healthy cells. This selective cytotoxicity is achieved by recognizing a conformational change in the cancerous p53-MDM2 complex present on the cell membrane of tumor cells. By restoring proper p53 function and triggering apoptosis, PNC-27 promotes cancer cell death while sparing normal, non-cancerous cells.

    • Selective Cancer Cell Targeting: Specifically targets and kills cancer cells without damaging healthy tissue.

    • Promotes Apoptosis: Induces programmed cell death in cancerous cells by interacting with the p53 protein.

    • Reduces Tumor Growth: Effectively reduces the size and spread of various tumor types.

    • Minimal Damage to Healthy Cells: Exhibits minimal toxicity in non-cancerous cells, reducing side effects.

    • Improves Cancer Treatment Outcomes: Enhances the effectiveness of traditional cancer therapies by targeting resistant cancer cells.

    • Broad Anticancer Application: Shows potential across a wide range of cancers, particularly those with mutated or dysfunctional p53.

    • Synergistic with Other Therapies: Can be used in conjunction with chemotherapy, radiation, or immunotherapy to improve cancer treatment outcomes.

    • Localized Action: When injected directly into tumors, PNC-27 provides localized anticancer effects with minimal systemic toxicity.

    • Novel Treatment Option: Offers an innovative approach for cancers resistant to traditional treatments.

    • Reduced Risk of Metastasis: Helps prevent the spread of cancer cells to other parts of the body.

    • Solid Tumors: Targets and induces apoptosis in solid tumor types, including breast, prostate, and lung cancer.

    • Pancreatic Cancer: Demonstrates selective cytotoxicity toward pancreatic cancer cells.

    • Colorectal Cancer: Induces cell death in colorectal cancer cells expressing mutant p53.

    • Liver Cancer: Shows efficacy in targeting hepatocellular carcinoma cells.

    • Ovarian Cancer: Effective in killing ovarian cancer cells with abnormal p53 expression.

    • Head and Neck Cancer: Reduces tumor growth in head and neck cancers with p53 mutations.

    • Melanoma: Effective in targeting melanomas with abnormal p53 expression.

    • Renal Cell Carcinoma: Shows potential in treating kidney cancers by selectively inducing cancer cell apoptosis.

    • Sarcomas: Reduces tumor size in soft tissue sarcomas by targeting p53-mutated cells.

    • Non-Hodgkin’s Lymphoma: May exhibit potential in selectively killing lymphoma cells with mutant p53.

    • Gelfand, M. L., & Sachar, M. (2016). PNC-27 as a novel cancer therapeutic targeting the p53 pathway. Cancer Research, 76(14), 4185-4193.

    • Rosenfeld, S., & Hoffman, R. M. (2017). Selective cytotoxicity of PNC-27 for p53-mutated cancer cells. Oncotarget, 8(4), 6672-6684.

    • Smith, B., & Zhang, W. (2017). PNC-27 peptide therapy: Mechanisms of action and clinical potential. Journal of Clinical Oncology, 35(18), e21392.

    • Uddin, M. N., et al. (2018). Therapeutic targeting of solid tumors using PNC-27. Cancer Cell International, 18, 66.

    • Baskaran, R., & Lee, J. (2018). The role of PNC-27 in pancreatic and liver cancer treatment. Journal of Hepatology, 69(2), 321-329.

    • Tanaka, T., & Ishikawa, T. (2019). PNC-27 as a potential treatment for ovarian cancer. Journal of Ovarian Research, 12(1), 18.

    • Li, X., et al. (2019). PNC-27's effects on melanoma and other skin cancers. Journal of Investigative Dermatology, 139(7), 1475-1481.

    • Huang, Y., & Wang, X. (2020). PNC-27 in the treatment of head and neck cancers. Cancer Medicine, 9(5), 1672-1681.